Pemvidutide: The Weight Loss Injection That Also Fixes Your Liver

Last updated: 4 June 2026 | Medically reviewed content — always consult your doctor

What if one weekly injection could help you lose weight and reverse fatty liver disease at the same time? That's exactly what pemvidutide is designed to do. Developed by US biotech company Altimmune, this dual-action drug activates both GLP-1 and glucagon receptors — tackling obesity from two angles simultaneously.

In clinical trials, pemvidutide has delivered 15.6% weight loss at 48 weeks while reducing liver fat by up to 76%. Even more impressively, it preserves lean muscle mass far better than most weight loss drugs — 78% of weight lost came from fat, not muscle.

Here's everything South Africans need to know about this promising dual agonist, including how it compares to Ozempic, survodutide, and other next-generation treatments.

What Is Pemvidutide and How Does It Work?

Pemvidutide is a balanced 1:1 GLP-1/glucagon dual receptor agonist. In simple terms, it activates two hormone pathways at once:

• GLP-1 receptor activation: Suppresses appetite, slows gastric emptying, improves blood sugar control — the same mechanism behind semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro)
• Glucagon receptor activation: Directly targets the liver — increases fat burning (lipolysis), reduces liver fat accumulation, and boosts resting energy expenditure

This dual approach is what makes pemvidutide unique among weight loss drugs. While Ozempic only activates GLP-1, and Mounjaro activates GLP-1 plus GIP, pemvidutide's glucagon component gives it a direct line to your liver — potentially making it the ideal treatment for people with both obesity and fatty liver disease.

Phase 2 Trial Results: MOMENTUM (Obesity)

The 48-week MOMENTUM trial tested pemvidutide in people with overweight or obesity. Participants were randomised to receive weekly injections of 1.2 mg, 1.8 mg, or 2.4 mg pemvidutide versus placebo:

Lean Mass Preservation: A Major Advantage

One of pemvidutide's standout features is its ability to preserve lean muscle mass during weight loss. On average, participants lost:

• 78.1% fat mass (the good kind of weight loss)
• Only 21.9% lean mass (much better than typical calorie restriction)

This is significant because many weight loss drugs — and crash diets — cause substantial muscle loss alongside fat loss. Losing muscle slows your metabolism and makes weight regain more likely. Pemvidutide's glucagon component may increase energy expenditure in a way that preferentially burns fat rather than breaking down muscle protein.

Phase 2b Trial Results: IMPACT (Fatty Liver/MASH)

For South Africans with fatty liver disease — an increasingly common condition linked to obesity, high-sugar diets, and sedentary lifestyles — pemvidutide's IMPACT trial results are particularly exciting:

• 76% reduction in liver fat at 24 weeks
• 59.1% MASH resolution without worsening fibrosis (primary endpoint met)
• Significant improvements in Enhanced Liver Fibrosis (ELF) score at 48 weeks
• Significant improvements in Liver Stiffness Measurement (LSM) at 48 weeks
• Weight loss of 5.0% (1.2 mg) and 6.2% (1.8 mg) in the MASH population at 24 weeks, with additional weight loss at 48 weeks still not plateauing
• 85% of pemvidutide-treated patients completed 48 weeks of therapy (vs 77% placebo)

Side Effects and Tolerability

Pemvidutide has demonstrated what researchers describe as "best-in-class tolerability" — particularly notable given that GI side effects are the main reason people stop taking weight loss injections:

Key safety points:

• GI side effects were generally mild to moderate and occurred mainly in the first 8 weeks
• Less than 1% of patients stopped treatment due to side effects (compare this to 5-7% for semaglutide and 7-10% for tirzepatide in trials)
• No cardiac safety concerns — no imbalance in cardiac adverse events vs placebo
• The 1.2 mg and 1.8 mg doses required no dose titration, simplifying treatment

How Pemvidutide Compares to Other Weight Loss Drugs

Who Might Benefit Most from Pemvidutide?

Based on the trial data, pemvidutide may be particularly suited for:

• People with fatty liver disease (MASH/NAFLD) — the glucagon component directly targets liver fat
• People concerned about muscle loss — 78% fat-selective weight loss is industry-leading
• Those who struggled with GI side effects on other injectables — <1% discontinuation rate
• People who don't want dose titration — 1.2 mg and 1.8 mg doses work without a ramp-up period

South African Availability Timeline

Can South Africans Access Pemvidutide Before Approval?

Under Section 21 of the Medicines Act, your doctor can apply to SAHPRA for access to unregistered medicines on a named-patient basis. This becomes possible once the drug receives approval in at least one major market (typically FDA or EMA). Requirements include:

• A prescription from a registered specialist (endocrinologist, hepatologist, or bariatrician)
• Documentation that approved alternatives have failed or are unsuitable
• Patient informed consent
• SAHPRA Section 21 application approval

Cost under Section 21 access would likely be R6,000-R10,000 per month (estimated based on similar biologics), as medical aid schemes won't cover unapproved treatments.

Estimated ZAR Pricing

While no official pricing exists for South Africa, based on the US market for similar weekly injectables and the ZAR/USD exchange rate:

• Estimated monthly cost: R4,000 - R8,000 (once commercially available)
• Medical aid coverage: Likely covered under chronic benefits for patients with BMI ≥35 and comorbidities (diabetes, MASH), pending SAHPRA registration and formulary inclusion
• Discovery Health / Bonitas / Momentum: Coverage decisions will depend on Phase 3 outcomes and cost-effectiveness analysis vs existing options

The Bigger Picture: Why Dual Agonists Matter

Pemvidutide represents a shift in weight loss medicine from single-target drugs to multi-receptor approaches. The next-generation pipeline includes several dual and triple agonists:

What You Can Do Now While Waiting

Pemvidutide won't reach South African pharmacies for several years, but you don't have to wait to start addressing weight and liver health:

• Currently available: Ozempic (semaglutide) is available at Dis-Chem and Clicks from ~R3,500/month with a doctor's prescription
• Liver-friendly diet: Reduce sugar, alcohol, and refined carbs. Focus on high-protein foods like eggs, chicken, fish, and biltong
• Exercise: Both cardio and resistance training reduce liver fat and preserve muscle mass
• Intermittent fasting: Time-restricted eating has been shown to reduce liver fat by 20-30% in some studies
• Rooibos tea: South African research suggests rooibos may have hepatoprotective effects and support metabolic health
• Get tested: Ask your GP for a liver function test (LFT) and FibroScan if you carry excess weight around your midsection

The Bottom Line

Pemvidutide stands out in an increasingly crowded weight loss drug pipeline for three reasons: it dramatically reduces liver fat (76%), it preserves lean muscle mass (78% of weight loss from fat), and it's exceptionally well-tolerated (<1% discontinuation). For the millions of South Africans dealing with both excess weight and fatty liver disease, a single weekly injection addressing both conditions is a compelling prospect.

While we wait for Phase 3 data and eventual SAHPRA approval, the existing evidence suggests pemvidutide will have an important role — particularly for patients where liver health is a primary concern alongside weight management.